Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of inflammatory bowel disease

51Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Leukocyte infiltration, improved levels of intercellular adhesion molecule 1 (ICAM-1), and oxidative stress in the colon are the principal factors in inflammatory bowel disease. The goal of the current study was to explore the effects of adelmidrol, an analog of the anti-inflammatory fatty acid amide signaling molecule palmitoylethanolamide, in mice subjected to experimental colitis. Additionally, to clarify whether the protective action of adelmidrol is dependent on the activation of peroxisome proliferatoractivated receptors (PPARs), we investigated the effects of a PPARγ antagonist, GW9662, on adelmidrol action. Adelmidrol (10mg/kg daily, o.s.) was tested in a murine experimentalmodel of colitis induced by intracolonic administration of dinitrobenzene sulfonic acid. Nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase, as well as tumor necrosis factor-α and interleukin-1β, were significantly increased in colon tissues after dinitrobenzene sulfonic acid administration. Immunohistochemical staining for ICAM-1, P-selectin, nitrotyrosine, and poly(ADP)ribose showed a positive staining in the inflamed colon. Treatment with adelmidrol decreased diarrhea, body weight loss, and myeloperoxidase activity. Adelmidrol treatment, moreover, reduced nuclear factor-κB translocation, cyclooxygenase-2, and phosphoextracellular signal-regulated kinase expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon. It also decreased the upregulation of ICAM-1 and P-selectin. Adelmidrol treatment produced a reduction of Bax and an intensification of Bcl-2 expression. This study clearly demonstrates that adelmidrol exerts important anti-inflammatory effects that are partly dependent on PPARγ, suggesting that this molecule may represent a new pharmacologic approach for inflammatory bowel disease treatment.

References Powered by Scopus

Crohn's disease

1671Citations
N/AReaders
Get full text

Ulcerative colitis

1657Citations
N/AReaders
Get full text

Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemie myocardium

905Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Anti-inflammatory and anti-oxidant activity of hidrox® in rotenone-induced Parkinson’s disease in mice

121Citations
N/AReaders
Get full text

Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases

114Citations
N/AReaders
Get full text

The antioxidant and anti-inflammatory properties of Anacardium occidentale l. Cashew nuts in a mouse model of colitis

78Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cordaro, M., Impellizzeri, D., Gugliandolo, E., Siracusa, R., Crupi, R., Esposito, E., & Cuzzocrea, S. (2016). Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of inflammatory bowel disease. Molecular Pharmacology, 90(5), 549–561. https://doi.org/10.1124/mol.116.105668

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

Researcher 11

69%

PhD / Post grad / Masters / Doc 5

31%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

69%

Pharmacology, Toxicology and Pharmaceut... 2

13%

Biochemistry, Genetics and Molecular Bi... 2

13%

Nursing and Health Professions 1

6%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
References: 1

Save time finding and organizing research with Mendeley

Sign up for free
0